11/4/2026

speaker
Conference Operator
Operator

Good morning and welcome to the New Vectus Pharma Third Quarter 2026 Financial Results and Business Update conference call. At this time, all participants are in a listen-only mode. Following the prepared remarks, we will conduct a question and answer session. As a reminder, this call is being recorded. I would like to now turn the call over to Ron Bentsur, Chairman and CEO of New Vectus Pharma. Please go ahead.

speaker
Ron Bentsur
Chairman and Chief Executive Officer, New Vectus Pharma

Thank you and good morning, everyone. Before we begin, I would like to remind everyone that statements made during this call that are not historical facts are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and our interpretation of information available to date, and they are subject to substantial risks and uncertainties that could cause actual results to differ materially. for a discussion of these risks, please refer to the section titled Risk Factors in our quarterly report on Form 10-Q for the quarter ended September 30th, 2026 and our other filings with the SEC. These risks are not exhaustive and new risks emerge from time to time. Any forward-looking statements made on this call speak only as of today, Wednesday, November 4th, 2026. and Nevectis undertakes no obligation to update or revise them except as required by law. Okay, now let's get to the interesting part of this call. Today's the first time we're hosting a call alongside the release of our quarterly results and the reason is simple. The third quarter was transformational for Nevectis and we have a great deal to share with you. We have transformed Nevectis into a late stage development company with the addition of two exciting drug candidates with best-in-class potential through our licensing agreement for ex-China rights with our new partner, Haisco. These additions have fundamentally changed the opportunity ahead of us. Our lead drug candidate, ciprocopan, which we also interchangeably refer to as NXP100, is an oral complement factor B inhibitor for once daily oral administration that is approved in China for the treatment of newly diagnosed paroxysmal nocturnal hemoglobinuria, or PNH in short, and in development for the treatment of other complement mediated diseases, including an ongoing phase three study in IgA nephropathy, a phase two study in lupus nephritis, both being conducted in China by our partner, Haisco. The second drug, NXP-200, is an oral brain penetrant paradox breaker BRAF inhibitor for the treatment of BRAF mutated solid tumors and I'll expand on these two products and on our legacy compound NXP 900 during the call. We closed the licensing deal with ISCO in late June, after which we completed a follow-on offering of $150 million in gross proceeds that was anchored by leading healthcare dedicated institutional investors. Also in the third quarter, we placed approximately $37 million with a single healthcare dedicated fund through our ATM facility. We ended the quarter with approximately $140 million in cash, which we expect will fund our operations into the second half of 2029, and importantly, beyond multiple value inflection points. Let's start with the key pipeline development highlights before taking a slightly deeper dive into our plans going forward. In July, Ciprocopan, or NXP100, received its first marketing approval in China for the treatment of patients with PNH who were not previously treated with complement inhibitors. The approval was based on a phase three study in which NXP100 demonstrated clear superiority versus Soliris on the primary and all key secondary endpoints. A second marketing application for ciprocopan in China is currently under review. This application covers patients with PNH who were previously treated with C5 inhibitors and is supported by another very successful phase three study in this patient population. We expect AISCO to announce this approval in the first quarter of 2027. We are in active dialogue with the FDA about our development plan for PNH in the US. These discussions are going well and we feel that the FDA is very engaged. We expect to provide an update on the FDA interaction by year end. Several additional phase two and phase three studies with NXP100 are ongoing. were also carefully watching the phase two and phase three studies being conducted with Fabalta or Tacopan, Novartis' twice-a-day oral complement factor B inhibitor. All these study results could provide an excellent roadmap for the additional indications that we may want to pursue with NXP100. We expect the coming months to be packed with important relevant news on the NXP100 front. Turning to NXP200, in September, the drug was granted the drug candidate was granted breakthrough designation in China for the treatment of BRAF V600 mutant recurrent or progressive high-grade glioma. In October, NXP200 was the subject of an oral presentation at the ESMO conference. Updated phase 1b data from a study in China demonstrated deep and durable single agent activity with NXP200, including complete responses in patients with recurrent or progressive gliomas Importantly, responses were also observed in patients previously treated with a BRAF inhibitor. Both of these aspects, complete responses and responses in BRAF relapse patients, could be meaningful points of differentiation for NXP200 compared to the other second-generation BRAF inhibitors in development. The emerging clinical profile for NXP200 demonstrates best-in-class potential. NXP200 is currently being investigated in a broad clinical program in China, to unlock its full therapeutic potential. For our legacy NXP 900 oncology candidate, the Phase 1B program continues. This includes ongoing osemeritinib and rilatinib combination studies and the planned investigator-initiated study of NXP 900 in combination with the newly approved KRAS inhibitor, durexin racid, and pancreatic cancer. This investigator-initiated study will be led by two top medical centers in the country. So as you can see, we're off to a very good start on all fronts since completing the licensing deal in late June. Now let's take a closer look at our plans for each program. Importantly, we're doing so from a very strong financial position with estimated cash runway into the second half of 2029. Let's start with Cipropican or NXP 100. NXP 100 inhibits factor B of the complement system. Factor B is a key component of the alternative pathway one of three pathways of the complement system. By inhibiting factor B, NXP100 blocks the amplification of the alternative pathway while preserving the other two. PNH and other complement mediated diseases result from uncontrolled complement activation. Blocking different targets within the complement system has proven to be a very successful strategy. Treatments like Soliris, Altamiris, and Fabalta are approved in several different indications and generate significant revenue. As I mentioned, the first approval of NXP100 in China was based on a randomized head-to-head Phase III study versus Solaris in treatment-naive PNH patients. NXP100 was superior to Solaris on the primary endpoint and all key secondary endpoints. The second marketing application in China that is currently under review is based on a Phase III study conducted in patients with PNH who failed treatment with a C5 inhibitor. This study also met the primary endpoint and key secondary endpoints with plenty of room to spare. It's important to mention that the overall hemoglobin increase demonstrated by NXP100 in the Phase III studies conducted were rather unprecedented, with average hemoglobin increases of 5 and 4.4 grams per deciliter in the treatment-naive and previously treated studies, respectively. and more. Importantly, the safety profile of NXP100 appears consistent with that of other complement inhibitors. Okay, so what does the opportunity in PNH look like for NXP100? The PNH market is estimated to be around $5 billion today and is expected to double within the next 8 to 10 years. Historically, This market has been dominated by the injectable C5 inhibitors, which were the centerpiece of AstraZeneca's $39 billion acquisition of Alexion in 2021. Factor B inhibitors offer the potential for better efficacy compared to the C5 inhibitors, along with the convenience of oral administration. So, with much better efficacy and this convenience advantage, we expect the factor B inhibitors to become the leading class in PNH over time. As of today, the only FDA-approved factor B inhibitor is Fibalta from Novartis. Fibalta is approved for PNH, IgA nephropathy, and C3G, a smaller nephrology indication, and is off to a fast start. It is on an annualized run rate of approximately a billion dollars already, and this is about two years out of the gate. We see a potentially substantial advantage for NXP100 in its once-daily dosing compared to the twice-per-day for Fibalta. this convenience advantage could be very meaningful and should not be underestimated in chronic diseases like PNH that require continuous lifelong treatment. I think most of you would agree that there's nothing easier for a patient suffering from a condition requiring lifelong therapy than a once a day oral treatment. And as you have likely gathered by now, PNH is only the beginning. In China, NXP100 is in an ongoing phase three study in IgA nephropathy. following a successful 24-week Phase II study. In the study, NXP100 demonstrated a statistically significant and clinically meaningful reduction in proteinuria. And importantly, the study also showed an almost three-point increase in EGFR in the NXP100 arm compared to a 1.5-point decline in the placebo arm over this 24-week time horizon. We know that there's a lot of excitement around the Aprilbath class of drugs in the IgA nephropathy space, and for good reason. In IgA nephropathy, the new standard established by the best Aprilbath drugs is the ability to stabilize EGFR long term, and that is considered disease modifying. It appears that Fabalta comes up just shy of being able to do that, whereas NXP100, based on the Phase II data generated, definitely has the potential to deliver that. This is where the favorable pharmacokinetic and pharmacodynamic profile of NXP100 versus Fibalta may be coming into play. Hence, NXP100 has the potential to deliver this competitive efficacy, which can compare to the best April baths, but with the clear convenience advantage of once daily oral dosing versus the April baths, which are all injectables. Together, the P&H and IGN nephropathy markets alone are estimated to exceed $20 billion within the next 10 years. Our priority is to advance NXP 100 towards a marketing application in the United States for P&H. We also see significant potential in additional indications. Our U.S. regulatory efforts in P&H are well underway. with two positive phase three studies from China. We believe we have a strong clinical data package. This puts us in a good position as we work with the FDA to define the U.S. regulatory path. We continue to have constructive dialogue with the FDA, which as I mentioned before, we feel is very engaged. We expect to provide an update on the U.S. regulatory path before year end. In addition, we're planning to submit an IND for another indication outside of P&H later this year. We also plan to initiate clinical trials in additional indications in the first half of 2027. Novartis is currently running five Phase II and Phase III clinical trials for Fabalta in additional indications beyond the three approvals that they already have. These studies include areas such as dry AMD and mastenia gravis. We eagerly await the results from the Fabalta and Haisco-run clinical trials. These results will help inform additional indications for us to pursue and where to focus our resources. As you can appreciate, there's no shortage of opportunities where we believe Cipropocan or NXP100 can work and be very impactful. Our job is to prioritize these opportunities carefully, taking into account the clinical and regulatory path, market potential, and our resources. Stay tuned for further updates on PNH and additional opportunities later in the year and into early 2027. To support our development efforts in complement, we have made several key hires towards this end. These include Dr. Dustin Little, who joined us in September as senior vice president, head of the complement program. Dr. Little is a physician, scientist, and board-certified nephrologist with a decade of industry experience at AstraZeneca, having most recently served as the global clinical head late cardiovascular, renal, and metabolism, providing clinical leadership for renal disease area strategy at AstraZeneca, as well as multiple first-in-class or potential first-in-class treatments for people living with kidney, cardiovascular, or hematologic diseases. Dr. Little brings a wealth of complement knowledge and experience in the nephrology, hematology settings. and he has really hit the ground running for us and is fully immersed in all facets of the NXP100 program. Now let's switch gears and talk about NXP200. BRAF is a commercially validated target in oncology with first-generation BRAF inhibitors generating well over $4 billion in combined annual revenue. While initially effective, first-generation BRAF inhibitors often cause paradoxical activation of the MAP kinase pathway. This results in treatment resistance and that is why the BRAFs are then combined with a MEK inhibitor to try to prolong the treatment effect. First generation inhibitors also do not address class two and class three BRAF mutations. There's a clear need to try to overcome the paradoxical activation of the existing BRAF inhibitors and the paradox breakers such as NXP200 represent the next generation approach to targeting BRAF. Last week, we reported updated data from the Phase 1b study in China with BRAF-mutated solid tumors conducted in China by Haisco. The study also included patients previously treated with BRAF and MEK inhibitors, and NXP200 generated responses in two of the three patients with this prior BRAF exposure. And this represents an important potential differentiator for NXP200. We also believe that NXP200 has the potential to expand beyond CNS tumors. Durable responses in non-small cell lung cancer, colorectal, and papillary thyroid cancers support the opportunity in a broad range of solid tumors, and further data from the ongoing Phase 1b study in China could substantiate this further. We should be receiving an update from this program in the next couple months in comparison Looking at data from the competitor paradox breakers being developed, it appears that these drugs are struggling to demonstrate meaningful activity outside of CNS tumors. Turning to the NXP200 data reported last week at the ESMO conference. In this 27-patient Phase 1b study, NXP200 demonstrated an objective response rate of 40% in the high-grade glioma cohort group, which included 20 patients. and this included three complete responses, two confirmed and one pending. The objective response rate was 42.9% in the low-grade glaucoma cord, including one confirmed complete response. The responses were assessed based on Raynaud 2.0 criteria, the FDA regulatory standard for brain tumors. I want to spend a moment on this assessment criteria because we've been asked how our results compare with data recently reported for another second generation BRF inhibitor. that company reported six responses out of nine patients or a 66.7% response rate in their glioma study. There's an important distinction in how the responses were assessed. The other companies reported results included radiographic responses rather than relying entirely on renal criteria. Based on their disclosure, only three of nine patients, or 33%, appear to have achieved a renal response with no complete responses. In the high-grade glioma group, only one out of five patients appeared to have achieved a renal response. This comparison reflects our interpretation only of that company's most recent disclosure. We remain on track to submit a US IND for NXP 200 by the end of the year with the goal of starting a US Phase 1B in early 2027. for some perspective on the opportunity. In April of this year, Servier acquired Day One Biopharmaceuticals for $2.5 billion. Day One's only approved drug, Agenda, is a first-generation BRAF inhibitor approved in pediatric low-grade glioma. At the time of the acquisition, Agenda was projected to generate $225 million to $250 million in sales this year, representing only approximately 7% of the current BRAF market, providing, we believe, an interesting benchmark for potential deals in this setting. Given the emerging profile in CNS and the potential in other solid tumors, we believe NXP200 could emerge as a best-in-class next-generation BRAF inhibitor in CNS and also across a much broader range of tumors. Now turning to NXP900. With a shift in our corporate focus towards NXP100, were concentrating NXP-900's development on the most promising combination opportunities. Two studies are ongoing with NXP-900 with Tegrizo-osimeritinib and Lubrena-lurlatinib, and we also have an investigator-initiated study plan for NXP-900 in combination with a newly approved KRAS inhibitor, Rasamq, or Derencov, I'll skip it. We expect to provide further NXP 900 clinical updates in the first half of 2027. Now to some financial results and cash runway information. I'd like to briefly review our third quarter financial results. Our net loss for the quarter was 30.1 million, excluding the upfront license payment and the one-time milestone associated with NXP 900 and the non-cash stock-based compensation. Our adjusted net loss was $5.8 million. We ended the quarter with approximately $140 million in cash. Based on our current plans, we expect that we have cash to fund operations into the second half of 2029. With that runway, we have the financial strength to reach multiple value inflection points across our pipeline. So looking ahead, we have a number of important catalysts over the next several months. For NXP100, we expect to provide an update on the U.S. regulatory path for PNH, as well as an IND filing by year end. We also anticipate regulatory approval in China for previously treated PNH patients in the first quarter of 2027, and near-term clinical updates from the Fabalta and the Jaisco-run clinical trials, which all could provide important data read-throughs for NXP100. For NXP 200, we're targeting a US IND filing by year end. We also expect additional data from the Phase 1B study in China across solid tumors, including colorectal melanoma, non-small cell lung, and papillary thyroid cancers in early 2027. And for NXP 900, we expect clinical updates from the Phase 1B program in the first half of 2027. We have several opportunities to deliver meaningful news in the near term, with the potential to create significant value across our pipeline. As I look at Novectis today, I see a very different company. NXP100 is a once-daily oral factor B inhibitor already approved in China for PNH with the potential to become a best-in-class treatment. NXP200 is a next-generation BRAF inhibitor with breakthrough therapy designation in China for high-grade glioma already achieved. It has the potential for significant differentiation in best-in-class attributes across multiple tumor types. NXP-900 adds further opportunities through our combination studies. At this time, I would like to thank our incredible partner, Haisco, for all their hard work and cooperation. We're privileged to be the shepherds for the NXP-100 and NXP-200 programs ex-China. I'm also deeply grateful to our team for an extraordinary last few months, and of course, Thank you all, our shareholders, for your continued trust and support. With that, operator, let's open it up for Q&A. Thank you.

speaker
Conference Operator
Operator

Thank you. We will now begin the question and answer session. We ask that you please limit yourself to one question and one follow-up. If you would like to ask a question, please press star 1 on your telephone keypad. A confirmation tone will indicate your line is in the question queue. You may press star 2 if you'd like to remove your question from the queue. For participants using speaker equipment, it may be necessary to pick up your handset before pressing the star keys.

Want transcripts like this in your own app? Try the Earnings call API, or read the transcript API docs.

Disclaimer

This conference call transcript was computer generated and almost certianly contains errors. This transcript is provided for information purposes only.EarningsCall, LLC makes no representation about the accuracy of the aforementioned transcript, and you are cautioned not to place undue reliance on the information provided by the transcript.

-

-

Use this data in your own app

Pull this call's transcript, audio and slides with the Earnings call transcripts API.

See pricing

9,000+ companies · REST API

Investor presentation